Aptar Pharma has unveiled two electronic drug delivery devices (eDevices) that take a patient-centric approach to drug delivery.
The e-Dose Counter and e-Lockout aim to improve patient compliance while being convenient to use.
The French manufacturer of nasal and pulmonary drug delivery devices says the e-Dose Counter is a cost-effective solution that meets regulatory recommendations for nasal and sub-lingual spray delivery of controlled substances.
The use of electronics allows the counting display to be large and highly visible, making it suitable for patients of all conditions and ages.
Electronics can also provide acoustic feedback and flashing displays inform and warn the patient if there is anything wrong.
The e-Lockout counts and displays the number of actuations and also prevents the device from being used for a period of time after a pre-defined number of actuations. Its locking system, which warns of overdosing, is recommended by regulators for nasal and sub-lingual spray delivery of controlled substances used in breakthrough pain management.
e-Lockout counts and displays the number of actuations
In addition the e-Lockout can also include patient aids and offer acoustic feedback as well as data transmission.
‘With all these innovative developments, Aptar Pharma is able to offer robust and cost-effective solutions for enhancing patient compliance. Smart devices will have an important role to play in integrated healthcare provider systems as these start to be deployed in the mid to long-term future,’ said Joachim Koerner, vice president of eDevice r&d, Aptar Pharma Prescription Division.
